Discovery of novel drug combinations for the treatment of bowel cancer

Discovery of novel drug combinations for the treatment of bowel cancer

Project details

Treatment outcomes for patients with metastatic bowel cancer remain poor, with most tumours developing resistance within two years. We are conducting high-throughput drug combination studies and are integrating drug treatment with genetic knock-out screens to identify novel therapeutic combinations. 

This project will validate and further develop lead combinations identified in our screening studies. Work will involve the use of bowel cancer cell lines and patient-derived organoid model systems, and make use of extensive molecular datasets for companion diagnostic development. Results will highlight novel therapeutic opportunities for improving outcomes for patients with bowel cancer.

About our research group

My research group has a major focus on bowel cancer genomics, the application of high-throughput molecular profiling technologies to identify principal cancer genes and biomarkers of cancer risk and prognosis. We are conducting next-generation sequencing and microarray studies involving large patient cohorts to define molecular signatures associated with tumour characteristics and outcome.

Patient-focused investigations are being complemented with functional studies on cancer cell lines to distinguish driver from passenger mutations and to gain insights into molecular pathways of carcinogenesis. Molecularly-annotated cancer cell lines are further being used to explore the efficacy of novel drug therapies, both as single-agents and in combination with standard therapies.

 

Researchers:

Associate Professor Oliver Sieber

Oliver Sieber
Associate Professor
Oliver
Sieber
Acting Division Head

Project Type: